In particular, we measured in mice blood, human IL-6, one of the most elevated cytokines during CRS, likely released by activated endothelial cells, as well as by activated macrophages stimulated by IFNγ, which represents the most relevant therapeutic target to manage CRS in humans. This evidence concerns the gene IL6 and congenital rubella syndrome.